AzTrials
AzTrials

Breast ReconstructionOPBC-02PREPECNCT04293146

Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC

A study testing pre-pectoral IBBR and sub-pectoral IBBR in people with Breast Reconstruction and Implant-Based Breast Reconstruction (IBBR), run by University Hospital, Basel, Switzerland at 22 sites in 7 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention… Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
pre-pectoral IBBR and sub-pectoral IBBR
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
382 participants
Where
22 sitesin 7 countries
Study dates
28 Jul 2020to Feb 2033
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent according to ICH/GCP regulations prior to any trial specific procedures
  • Patients undergoing NSM or SSM and IBBR in the therapeutic or risk-reducing Setting
  • Ability to complete the Quality of Life questionnaires

Who cannot join

  • No indication for IBBR according to clinical judgment of the treating surgeon
  • Skin flaps inadequate for pre-pectoral IBBR.

Trial locations and contacts

22 sites in 7 countries.

22 sites in 7 countries

Switzerland9 sites
  • Klinik Hirslanden Brustzentrum Aarau

    Aarau, 5000

  • Kantonsspital Aarau AG

    Aarau, 5001

  • University Hospital Basel, Division of Breast Surgery

    Basel, 4031

  • Universitätsklinik für Plastische- und Handchirurgie, Inselspital

    Bern, 3010

  • Lindenhof Bern

    Bern, 3011

  • Kantonsspital Frauenfeld

    Frauenfeld, 8501

  • Gesundheitszentrum Fricktal

    Rheinfelden, 4310

  • Ospedale Regionale di Lugano

    Viganello, 6962

  • Brust-Zentrum Zürich

    Zurich, 8008

Other trials in Switzerland

Germany4 sites
  • Evangelisches Krankenhaus BETHESDA zu Duisburg GmbH, Klinik für Frauenheilkunde, Geburtshilfe, Gynäkologische Onkologie & Senologie

    Duisburg

  • KEM | Evang. Kliniken Essen-Mitte

    Essen, 45136

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120

  • Landesfrauenklinik, Senologie und Brustzentrum

    Wuppertal

Other trials in Germany

Sweden3 sites
  • Capio S:t Görans Hospital

    Stockholm, 11281

  • Södersjukhuset

    Stockholm, 11281

  • Karolinska University Hospital

    Stockholm, 17176

Other trials in Sweden

Austria2 sites
  • Universitätsklinik für Frauenheilkunde und Geburtshilfe

    Salzburg, 5020

  • Medizinische Universität Wien

    Vienna, 1090

Other trials in Austria

Italy2 sites
  • Universitario "Agostino Gemelli" di Roma, Unità Operativa di Chirurgia Senologica

    Roma

  • Ospedale Santa Chiara, Breast Surgical Oncology/Oncoplastic Surgery. Breast Center

    Trento

Other trials in Italy

United States1 site
  • Brigham and Women's Hospital Harvard Medical School

    Boston, Massachusetts, 02115

Other trials in United States

Hungary1 site
  • National Institute of Oncology

    Budapest, 1122

Other trials in Hungary

About this study

Official title: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy (OPBC-02/ PREPEC): a Pragmatic, Multicenter, Randomized, Superiority Trial

This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.

Read the detailed description

This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR for patients undergoing skin-sparing mastectomy or nipple-sparing mastectomy for prevention or treatment of breast cancer.The aim is to adhere to standard of care as much as possible to follow the pragmatic trial design to generate data that are applicable to today's practice. Therefore, surgeons are allowed to use their preferred Acellular Dermal Matrix (ADM), synthetic meshes, expanders and implants, thereby offering practitioners considerable leeway in deciding how to perform the procedure. For the same reason, both the one- and two-staged IBBR approaches are allowed when studying pre- versus sub-pectoral IBBR.

Being tested
pre-pectoral IBBR, sub-pectoral IBBR
Keywords
skin-sparing mastectomy (SSM), nipple-sparing mastectomy (NSM), immediate breast reconstruction, pre-pectoral breast implant, sub-pectoral breast implant

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • pre-pectoral IBBRProcedure or surgery

    The breast is reconstructed by positioning a breast implant above (pre-pectoral) the pectoralis major muscle.

  • sub-pectoral IBBRProcedure or surgery

    The breast is reconstructed by positioning a breast implant below (sub-pectoral) the pectoralis major muscle.

Study groups in NCT04293146
Study groupRoleWhat they receive
pre-pectoral IBBRActive comparatorNot described
Receives: Procedure: pre-pectoral IBBR
sub-pectoral IBBRActive comparatorNot described
Receives: Procedure: sub-pectoral IBBR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in BREAST-Q scale

    compare the Quality of Life (QoL) with respect to long-term physical well-being (chest) after pre-pectoral or sub-pectoral IBBR. The BREAST-Q module specific to breast reconstruction version 2.0 consists of 13 independent scales covering health-related QoL domains and satisfaction domains. Each scale is scored to generate a numerical score on a scale from 0 (worst) to 100 (best).

    Measured: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)

  2. Change in EQ-5D-5L questionnaire

    The 5-level version of the EQ-5D (EQ-5D-5L) consists of the EQ-5D descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/Depression (5 answer levels each: no problems, slight problems, moderate problems, severe problems and extreme problems), resulting in a 1-digit number that expresses the level for that dimension. The digits for each dimension are combined into a 5-digit number that describes the patient's health state and is subsequently converted into a preference-based quality of life weight (utility) using an algorithm derived from population-based studies. In addition, patients are asked to rate their health on a vertical visual analogue scale (EQ VAS), where the anchors are labelled with 'The best health you can imagine' and 'The worst health you can imagine'.

    Measured: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)

Secondary outcomes (13)
  1. loss of expander or implant

    compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of loss of expander or implant. Loss of expander or implant is defined as an unplanned surgical removal of expander/implant with or without immediate replacement.

    Measured: within 24 months of undergoing mastectomy and immediate reconstruction

  2. surgical complications

    compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of surgical complications. The complications include: Wound dehiscence, Haematoma, Seroma, Implant/expander exposure/Extrusion, Implant/Expander rotation/malpositioning, Infection, Mastectomy skin flap necrosis, Capsular contraction, Lymphedema

    Measured: within 24 months of undergoing mastectomy and immediate reconstruction

  3. thromboembolic events

    compare the safety of pre-pectoral and sub-pectoral IBBR, in terms of thromboembolic events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Measured: within 24 months of undergoing mastectomy and immediate reconstruction

  4. patient satisfaction

    compare patient satisfaction after pre-pectoral or sub-pectoral IBBR

    Measured: over 24 months since mastectomy

  5. animation deformity

    compare animation deformity after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy

    Measured: before and 24 months after the mastectomy

  6. capsular contracture

    compare capsular contracture after pre-pectoral or sub-pectoral IBBR by using pictures from before and 24 months after the mastectomy

    Measured: before and 24 months after the mastectomy

  7. aesthetic results

    compare aesthetic results after pre-pectoral or sub-pectoral IBBR assessed by photographs of the breast taken in a standardized way. They will be evaluated by an experienced investigator who is blinded for group assignment. The blinded outcome assessment team will be trained to enter data for the two most widely used semi-automatic software for objective aesthetic evaluation, the 'Breast Cancer Conservative Treatment cosmetic results' (BCCT.core)

    Measured: before and 24 months after the mastectomy

  8. Recurrence-free survival (RFS)

    RFS is defined as the time from randomization until the first documentation of any of the following events: local-regional occurrence or recurrence of invasive disease or ductal carcinoma in situ (DCIS), distant breast cancer metastasis, or death from any cause.

    Measured: until 10 years after mastectomy and IBBR.

  9. aesthetic results evaluated by patients

    evaluated by patients using a four point scale: excellent, good, regular, bad.

    Measured: at baseline and after 24 months

  10. total number of operative procedures

    assess the burden on patients by total number of operative procedures

    Measured: until 24 months after mastectomy

  11. length of hospital stay (index hospitalization and overall)

    length of hospital stay (index hospitalization and overall) following randomization until discharge and the cumulative number of days the patient was hospitalized

    Measured: until 24 months after randomization

  12. total number of outpatient visits at the trial site and the emergency department

    assess the burden on patients by total number of outpatient visits at the trial site and the emergency department

    Measured: from admission for mastectomy until 24 months after randomization

  13. aesthetic results evaluated by local physicians

    evaluated by local physicians using a four point scale: excellent, good, regular, bad.

    Measured: at baseline and after 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2020
  2. Study start28 Jul 2020
  3. Primary completionMay 2025 (estimated)
  4. Study completionFeb 2033 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study will objectively assess the results and complication of two surgical techniques and thus provide evidence to assess whether there are differences between these techniques.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
382 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04293146
Sponsor's protocol ID
2020-00256; ch18Weber4
Acronym
OPBC-02PREPEC
Status last verified
Dec 2024
First submitted
21 Feb 2020
Last updated
13 Dec 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kappos EA, Schulz A, Regan MM, Moffa G, Harder Y, Ribi K, Potter S, Pusic AL, Fehr MK, Hemkens LG, Holzbach T, Farhadi J, Simonson C, Knauer M, Verstappen R, Bucher HC, Zwahlen D, Zimmermann F, Schwenkglenks M, Mucklow R, Shaw J, Bjelic-Radisic V, Chiorescu A, Chun YS, Farah S, Xiaosong C, Nigard L, Kuemmel S, Reitsamer R, Hauschild M, Fulco I, Tausch C, Fischer T, Sarlos D, Constantinescu MA, Lupatsch JE, Fitzal F, Heil J, Matrai Z, de Boniface J, Kurzeder C, Haug M, Weber WP. Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. BMJ Open. 2021 Sep 2;11(9):e045239. doi: 10.1136/bmjopen-2020-045239.

    PubMed 34475143

Questions about this trial

What is this clinical trial studying?

A study testing pre-pectoral IBBR and sub-pectoral IBBR in people with Breast Reconstruction and Implant-Based Breast Reconstruction (IBBR), run by University Hospital, Basel, Switzerland at 22 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 13 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 22 sites in Switzerland, Germany, Sweden, Austria, Italy and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in BREAST-Q scale (time frame: within 24 months after mastectomy (screening, day 10, and months 1, 6, 12 and 24)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04293146, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in